Erratum to "Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq™ 2.0 and an in-house method" (DOI:10.1016/j.jviromet.2009.03.021);Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq™ 2.0 and an in-house method

Journal of Virological Methods

Volumn 159, Issue 2, 2009, Pages 211-216

  Saravanan, S ^a   Vidya, M ^a   Balakrishanan, P ^a   Kumarasamy, N ^a   Solomon, Sunil S ^a   Solomon, S ^a   Kantor, Rami ^b   Katzenstein, David ^c   Ramratnam, Bharat ^b   Mayer, Kenneth H ^b  

^a YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^b BROWN UNIVERSITY   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Concordance; HIV 1 genotyping evaluation; In house HIV 1 drug resistance assay; Indeterminate rate; Mixtures; ViroSeq HIV 1 genotyping

Indexed keywords

PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ACCURACY; ANTIVIRAL RESISTANCE; ARTICLE; BIOASSAY; CODON; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; GENE AMPLIFICATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INDIA; INTERMETHOD COMPARISON; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; REPRODUCIBILITY; VALIDATION PROCESS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 67349212106     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2009.11.001     Document Type: Erratum

References (28)

1. Baxter J.D., Mayers D.L., Wentworth D.N., Neaton J.D., Hoover M.L., Winters M.A., Mannheimer S.B., Thompson M.A., Abrams D.I., Brizz B.J., Ioannidis J.P., and Merigan T.C. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 14 (2000) F83-F93
2. Beck I.A., Mahalanabis M., Pepper G., Wright A., Hamilton S., Langston E., and Frenkel L.M. Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors. J. Clin. Microbiol. 40 (2002) 1413-1419
3. Bennett D.E., Smith A.J., McCormick L., Prachand N., and Sey E. Categorization of HIV drug resistance using the WHO/CDC HIV drug resistance threshold survey method. Antivir. Ther. 11 (2006) S116
4. Boden D., Hurley A., Zhang L., Cao Y., Guo Y., Jones E., Tsay J., Ip J., Farthing C., Limoli K., Parkin N., and Markowitz M. HIV-1 drug resistance in newly infected individuals. JAMA 282 (1999) 1135-1141
5. Bowles E., Wensing A.M.J., and van de Vijver D.A.M.C. WATCH: a worldwide database for collecting and analysing data on transmission of drug resistant HIV using standardized methods. Program and abstracts of the 16th International AIDS Conference, August 13-18. Toronto, Canada (2006) (Abstract MOPE0388)
6. Church J.D., Towler W.I., Hoover D.R., Hudelson S.E., Kumwenda N., Taha T.E., Eshleman J.R., and Eshleman S.H. Comparison of LigAmp and an ASPCR assay for detection and quantification of K103N-containing HIV variants. AIDS Res. Hum. Retroviruses 24 (2008) 595-605
7. Durant J., Clevenbergh P., Halfon P., Delgiudice P., Porsin S., Simonet P., Montagne N., Boucher C.A., Schapiro J.M., and Dellamonica P. Drug resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet 353 (1999) 2195-2199
8. Gallant J.E. Antiretroviral drug resistance and resistance testing. Top. HIV Med. 13 (2006) 138-142
9. Geretti A.M. Epidemiology of antiretroviral drug resistance in drug-naïve persons. Curr. Opin. Infect. Dis. 20 (2007) 22-32
10. Grant P., and Zolopa A. Integrase inhibitors: a clinical review of raltegravir and elvitegravir. J. HIV Ther. 13 (2008) 36-39
11. He Y., Cheng J., Lu H., Li J., Hu J., Qi Z., Liu Z., Jiang S., and Dai Q. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 16332-16337
12. Johnson J.A., Li J.F., Wei X., Lipscomb J., Bennett D., Brant A., Cong M.E., Spira T., Shafer R.W., and Heneine W. Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations. PLoS ONE 2 (2007) e638
13. Kent D.M., McGrath D., Ioannidis J.P., and Bennish M.L. Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda. Clin. Infect. Dis. 37 (2003) S13-24
14. Kumarasamy N., Solomon S., Chaguturu S.K., Cecelia A.J., Vallabhaneni S., Flanigan T.P., and Mayer K.H. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin. Infect. Dis. 15 (2005) 1525-1528
15. Kuritzkes D.R. Preventing and managing antiretroviral drug resistance. AIDS Patient Care STDS 18 (2004) 259-273
16. Larder B.A., Kellam P., and Kemp S.D. Zidovudine resistance predicted by direct detection of mutation in DNA from HIV-infected lymphocytes. AIDS 5 (1991) 137-144
17. Lindstrom A., and Albert J. A simple and sensitive 'in-house' method for determining genotypic drug resistance of HIV-1. J. Virol. Methods 107 (2003) 45-51
18. Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., Koup R.A., Mellors J.W., Connick E., Conway B., Kilby M., Wang L., Whitcomb J.M., Hellmann N.S., and Richman D.D. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347 (2002) 385-394
19. ® sequencing system. Clin. Microbiol. 46 (2008) 4087-4090
20. Kumar S., Tamura K., and Nei M. MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief. Bioinform. 5 (2004) 150-163
21. Schuurman R., Demeter L., Reichelderfer P., Tijnagel J., de Groot T., and Boucher C. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J. Clin. Microbiol. 37 (1999) 2291-2296
22. Shafer R.W., Winters M.A., Palmer S., and Merigan T.C. Multiple concurrent reverse transcriptase and protease mutations multidrug resistance of HIV-1 isolates from heavily treated patients. Ann. Intern. Med. 128 (1998) 906-911
23. Steegen K., Demecheleer E., De Cabooter N., Nges D., Temmerman M., Ndumbe P., Mandaliya K., Plum J., and Verhofstede C. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance. J. Virol. Methods 133 (2006) 137-145
24. Tural C., Ruiz L., Holtzer C., Schapiro J., Viciana P., González J., Domingo P., Boucher C., Rey-Joly C., Clotet B., and Havana Study Group. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16 (2002) 209-218
25. Vega Y., Pérez-Alvárez L., Delgado E., Muñoz M., Casado G., Carmona R., Sierra M., Vázquez de Parga E., Pinilla M., García V., Medrano L., Contreras G., Thomson M., and Nájera R. Oligonucleotide ligation assay for detection of mutations associated with reverse transcriptase and protease inhibitor resistance in non-B subtypes and recombinant forms of human immunodeficiency virus type 1. J. Clin. Microbiol. 43 (2005) 5301-5304
26. Vella S. Antiretroviral drug resistance and HIV/AIDS in the developing world. J. HIV Ther. 7 (2002) 53-55
27. Villahermosa M.L., Beck I., Pérez-Alvarez L., Contreras G., Frenkel L.M., Osmanov S., de Parga E.V., Delgado E., Manjon N., Cuevas M.T., Thomson M.M., Medrano L., and Najera R. Detection and quantification of multiple drug resistance mutations in HIV-1 reverse transcriptase by an oligonucleotide ligation assay. J. Hum. Virol. 4 (2001) 238-248
28. WHO. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, November 3 (2008), Department of Health and Human Services 1-139